Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23967953 | 0.84 | PRMT6 (0.48) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16011810 | 0.83 | EGFR (0.47) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16011816 | 0.82 | GRIN2D (0.43) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL16011996 | 0.82 | PTK6 (0.47) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16024056 | 0.79 | BRD4 (0.48) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL16024047 | 0.77 | ERBB2 (0.61) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16011993 | 0.77 | MAPK14 (0.48) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16011997 | 0.76 | MAPK14 (0.43) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL17471213 | 0.75 | PTK6 (0.49) | MAPK14PTK6ALKEGFRERBB2 | |
| SCHEMBL16257469 | 0.74 | LRRK2 (0.53) | MAPK14PTK6ALKEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2964225-B1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2964225-B1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9951061-B2 | CaMKII inhibitors and uses thereof | ALLOSTEROS THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951061-B2 | CaMKII inhibitors and uses thereof | ALLOSTEROS THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951061-B2 | CaMKII inhibitors and uses thereof | ALLOSTEROS THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| WO-2016037106-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2964225-A1 | CaMKII INHIBITORS AND USES THEREOF | Allosteros Therapeutics Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138212-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138212-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | F3 3192/4885F2 4595/4885F10 3855/4885 |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | F3 3192/4885F2 4595/4885F10 3855/4885 |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | F3 3192/4885F2 4595/4885F10 3855/4885 |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | F3 3192/4885F2 4595/4885F10 3855/4885 |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | F3 3192/4885F2 4595/4885F10 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.